CMAUP Plant Collective Molecular Activities

Plant Name: Piper nigrum

Taxonomic Information:

Plant ID: NPO28928
Plant Latin Name: Piper nigrum
Taxonomy Genus: Piper
Taxonomy Family: Piperaceae

Plant External Links:

NCBI TaxonomyDB: 13216
Plant-of-the-World-Online: 682369-1

Used in Medicines:

Country/Region:

Brazil; Philippines; Indonesia; India; United States; China; Thailand; Iraq; Burkina Faso

Traditional Medicine System:

Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; Homeopathy

Geographical Distribution:

Brazil; Bangladesh; Guinea; Costa Rica; Cambodia; Cameroon; Burkina Faso; Benin; Cuba; Venezuela; China; Thailand; Haiti; Iraq; Philippines; Indonesia; Mauritius; Trinidad and Tobago; French Guiana; Dominican Republic; United States; Seychelles; Honduras; Mexico; India; Sri Lanka

Example Image

Geographical Distribution

See the Plant Occurrence Worldwide with Latitude and Longitude Available

Collective Molecular Activities of the Plant

List of Human Proteins Collectively Targeted by the Plant

Target Activity Range: ≤ 1μM
Click Gene ID to Access Activity Profile of Individual Target

Target Class	Target Proteins
Small molecule receptor (family A GPCR)	ADRA1B; HTR7; FFAR1; FFAR4; ADRA1A; ADRA2C; ADRB1; ADRB2; ADRA1D; ADRA2A; DRD3; DRD2; CNR2; HTR2B; HTR2A; HTR1A; HTR2C;
Enzyme_unclassified	TDP1; ALDH1A1; ALOX15;
Nicotinic acetylcholine receptor	CHRNA3;
Transient receptor potential channel	TRPV1;
Potassium channels	KCNH2;
Nuclear hormone receptor subfamily 1 group C	PPARA;
Oxidoreductase	MAOB;
SLC superfamily of solute carriers	SLC6A4;
Unclassified	LMNA; FABP3; FABP5; FABP4;

List of Human Cytochrome P450 Enzymes Affected by the Plant

Activity Range: ≤ 1μM
Click Gene ID to Access Activity Profile of Individual Enzyme

Cytochrome P450 Enzymes:	CYP2C19; CYP2C9; CYP3A4;

Detailed Information of Target Proteins

Protein Class	Gene ID	Protein Name	Uniprot ID	Target ChEMBL ID
Cytochrome P450 family 2	CYP2C19	Cytochrome P450 2C19	P33261	CHEMBL3622
Cytochrome P450 family 2	CYP2C9	Cytochrome P450 2C9	P11712	CHEMBL3397
Cytochrome P450 family 3	CYP3A4	Cytochrome P450 3A4	P08684	CHEMBL340
Enzyme_unclassified	ALOX15	Arachidonate 15-lipoxygenase	P16050	CHEMBL2903
Enzyme_unclassified	TDP1	Tyrosyl-DNA phosphodiesterase 1	Q9NUW8	CHEMBL1075138
Enzyme_unclassified	ALDH1A1	Aldehyde dehydrogenase 1A1	P00352	CHEMBL3577
Nicotinic acetylcholine receptor	CHRNA3	Neuronal acetylcholine receptor subunit alpha-3	P32297	CHEMBL3068
Nuclear hormone receptor subfamily 1 group C	PPARA	Peroxisome proliferator-activated receptor alpha	Q07869	CHEMBL239
Oxidoreductase	MAOB	Monoamine oxidase B	P27338	CHEMBL2039
Potassium channels	KCNH2	HERG	Q12809	CHEMBL240
SLC superfamily of solute carriers	SLC6A4	Serotonin transporter	P31645	CHEMBL228
Small molecule receptor (family A GPCR)	ADRA1B	Alpha-1b adrenergic receptor	P35368	CHEMBL232
Small molecule receptor (family A GPCR)	HTR7	Serotonin 7 (5-HT7) receptor	P34969	CHEMBL3155
Small molecule receptor (family A GPCR)	FFAR1	Free fatty acid receptor 1	O14842	CHEMBL4422
Small molecule receptor (family A GPCR)	FFAR4	G-protein coupled receptor 120	Q5NUL3	CHEMBL5339
Small molecule receptor (family A GPCR)	ADRA1A	Alpha-1a adrenergic receptor	P35348	CHEMBL229
Small molecule receptor (family A GPCR)	ADRA2C	Alpha-2c adrenergic receptor	P18825	CHEMBL1916
Small molecule receptor (family A GPCR)	ADRB1	Beta-1 adrenergic receptor	P08588	CHEMBL213
Small molecule receptor (family A GPCR)	ADRB2	Beta-2 adrenergic receptor	P07550	CHEMBL210
Small molecule receptor (family A GPCR)	ADRA1D	Alpha-1d adrenergic receptor	P25100	CHEMBL223
Small molecule receptor (family A GPCR)	ADRA2A	Alpha-2a adrenergic receptor	P08913	CHEMBL1867
Small molecule receptor (family A GPCR)	DRD3	Dopamine D3 receptor	P35462	CHEMBL234
Small molecule receptor (family A GPCR)	DRD2	Dopamine D2 receptor	P14416	CHEMBL217
Small molecule receptor (family A GPCR)	CNR2	Cannabinoid CB2 receptor	P34972	CHEMBL253
Small molecule receptor (family A GPCR)	HTR2B	Serotonin 2b (5-HT2b) receptor	P41595	CHEMBL1833
Small molecule receptor (family A GPCR)	HTR2A	Serotonin 2a (5-HT2a) receptor	P28223	CHEMBL224
Small molecule receptor (family A GPCR)	HTR1A	Serotonin 1a (5-HT1a) receptor	P08908	CHEMBL214
Small molecule receptor (family A GPCR)	HTR2C	Serotonin 2c (5-HT2c) receptor	P28335	CHEMBL225
Transient receptor potential channel	TRPV1	Vanilloid receptor	Q8NER1	CHEMBL4794
Unclassified	LMNA	Prelamin-A/C	P02545	CHEMBL1293235
Unclassified	FABP3	Fatty acid binding protein muscle	P05413	CHEMBL3344
Unclassified	FABP5	Fatty acid binding protein epidermal	Q01469	CHEMBL3674
Unclassified	FABP4	Fatty acid binding protein adipocyte	P15090	CHEMBL2083

Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)

Detailed Information of Enriched Gene Ontolgy

GO Type	GO Category	Enriched GO Terms	p-Value	Adjusted p-Value	Enriched Genes
MF	GO:0005488; binding	GO:0051378; serotonin binding	4.860E-12	2.759E-09	HTR1A, HTR2A, HTR2B, HTR2C, HTR7
BP	GO:0009987; cellular process	GO:0007210; serotonin receptor signaling pathway	4.402E-10	1.653E-07	HTR1A, HTR2A, HTR2B, HTR2C, HTR7
MF	GO:0060089; molecular transducer activity	GO:0004993; G-protein coupled serotonin receptor activity	4.402E-10	1.653E-07	HTR1A, HTR2A, HTR2B, HTR2C, HTR7
MF	GO:0005488; binding	GO:0051379; epinephrine binding	4.916E-10	1.755E-07	ADRA2A, ADRA2C, ADRB1, ADRB2
BP	Unclassified;	GO:0045907; positive regulation of vasoconstriction	2.431E-09	7.154E-07	ADRA1A, ADRA1B, ADRA1D, ADRA2C, HTR2A
MF	GO:0060089; molecular transducer activity	GO:0004937; alpha1-adrenergic receptor activity	4.543E-09	1.237E-06	ADRA1A, ADRA1B, ADRA1D
BP	GO:0051179; localization	GO:0051209; release of sequestered calcium ion into cytosol	1.234E-08	3.018E-06	DRD2, HTR2A, HTR2B, HTR2C, TRPV1
BP	GO:0065007; biological regulation	GO:0001994; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	1.815E-08	4.075E-06	ADRA1A, ADRA1B, ADRA1D
BP	GO:0009987; cellular process	GO:0070374; positive regulation of ERK1 and ERK2 cascade	3.521E-08	7.218E-06	ADRA1A, ALOX15, DRD2, FFAR4, HTR2A, HTR2B, HTR2C
BP	GO:0008152; metabolic process	GO:0010513; positive regulation of phosphatidylinositol biosynthetic process	4.532E-08	8.812E-06	HTR2A, HTR2B, HTR2C
MF	GO:0005488; binding	GO:0051380; norepinephrine binding	4.532E-08	8.812E-06	ADRA2A, ADRB1, ADRB2
BP	GO:0008152; metabolic process	GO:0016098; monoterpenoid metabolic process	9.054E-08	1.657E-05	CYP2C19, CYP2C9, CYP3A4
MF	GO:0005488; binding	GO:0005504; fatty acid binding	1.205E-07	2.168E-05	FABP3, FABP4, FABP5, FFAR4
BP	GO:0009987; cellular process	GO:0014062; regulation of serotonin secretion	1.583E-07	2.735E-05	HTR1A, MAOB, SLC6A4
BP	GO:0032501; multicellular organismal process	GO:0031649; heat generation	2.529E-07	4.050E-05	ADRB1, ADRB2, TRPV1
BP	GO:0009987; cellular process	GO:0002031; G-protein coupled receptor internalization	7.426E-07	1.064E-04	DRD2, DRD3, HTR2B
BP	GO:0050896; response to stimulus	GO:0042738; exogenous drug catabolic process	9.890E-07	1.389E-04	CYP2C19, CYP2C9, CYP3A4
BP	GO:0050896; response to stimulus	GO:0009725; response to hormone	1.111E-06	1.541E-04	ADRA1A, ADRA2A, CHRNA3, FABP3, FFAR4, MAOB, PPARA, SLC6A4, TRPV1
BP	Unclassified;	GO:2000021; regulation of ion homeostasis	1.261E-06	1.726E-04	DRD2, DRD3, HTR2A, HTR2B, HTR2C, TRPV1
BP	GO:0051179; localization	GO:0043270; positive regulation of ion transport	2.754E-06	3.447E-04	ADRA2A, ADRB2, DRD2, FFAR1, KCNH2, SLC6A4
BP	GO:0009987; cellular process	GO:0007208; phospholipase C-activating serotonin receptor signaling pathway	2.830E-06	3.482E-04	HTR2A, HTR2C
MF	GO:0005488; binding	GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	2.830E-06	3.482E-04	HTR2A, HTR2C
BP	GO:0007610; behavior	GO:0048148; behavioral response to cocaine	5.077E-06	5.556E-04	DRD2, DRD3, HTR2A
BP	GO:0009987; cellular process	GO:0060160; negative regulation of dopamine receptor signaling pathway	8.482E-06	8.395E-04	DRD2, DRD3
MF	GO:0060089; molecular transducer activity	GO:0004938; alpha2-adrenergic receptor activity	8.482E-06	8.395E-04	ADRA2A, ADRA2C
BP	GO:0065007; biological regulation	GO:0007202; activation of phospholipase C activity	8.973E-06	8.722E-04	ADRA1A, HTR2A, HTR2B
BP	GO:0008152; metabolic process	GO:0019433; triglyceride catabolic process	1.018E-05	9.734E-04	FABP3, FABP4, FABP5
BP	GO:0050896; response to stimulus	GO:0001975; response to amphetamine	1.150E-05	1.093E-03	CNR2, DRD2, DRD3
BP	GO:0009987; cellular process	GO:0050873; brown fat cell differentiation	1.446E-05	1.345E-03	ADRB1, ADRB2, FABP4
BP	GO:0009987; cellular process	GO:0014059; regulation of dopamine secretion	1.446E-05	1.345E-03	DRD2, DRD3, HTR2A
BP	GO:0009987; cellular process	GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway	1.695E-05	1.522E-03	HTR1A, HTR7
BP	GO:0065007; biological regulation	GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway	1.695E-05	1.522E-03	ADRA2A, ADRA2C
BP	GO:0009987; cellular process	GO:0032811; negative regulation of epinephrine secretion	1.695E-05	1.522E-03	ADRA2A, ADRA2C
MF	GO:0003824; catalytic activity	GO:0034875; caffeine oxidase activity	1.695E-05	1.522E-03	CYP2C9, CYP3A4
BP	GO:0065007; biological regulation	GO:0007194; negative regulation of adenylate cyclase activity	2.178E-05	1.882E-03	ADRA2A, DRD2, DRD3
BP	GO:0023052; signaling	GO:0032228; regulation of synaptic transmission, GABAergic	2.178E-05	1.882E-03	ADRA1A, CNR2, DRD2
BP	GO:0032501; multicellular organismal process	GO:0042596; fear response	2.178E-05	1.882E-03	ADRB1, HTR1A, HTR2C
BP	GO:0051179; localization	GO:0043266; regulation of potassium ion transport	2.277E-05	1.937E-03	ADRA2A, DRD2, HTR2A, KCNH2
BP	GO:0032501; multicellular organismal process	GO:0045987; positive regulation of smooth muscle contraction	2.622E-05	2.163E-03	ADRA1A, ADRA1B, ADRA1D
MF	GO:0003824; catalytic activity	GO:0008395; steroid hydroxylase activity	2.622E-05	2.163E-03	CYP2C19, CYP2C9, CYP3A4
BP	GO:0050896; response to stimulus	GO:0071502; cellular response to temperature stimulus	2.821E-05	2.275E-03	HTR2B, TRPV1
BP	GO:0040011; locomotion	GO:0090325; regulation of locomotion involved in locomotory behavior	2.821E-05	2.275E-03	DRD2, DRD3
BP	GO:0009987; cellular process	GO:0050709; negative regulation of protein secretion	5.209E-05	3.919E-03	ADRA2A, DRD2, DRD3, FFAR4
BP	GO:0065007; biological regulation	GO:0042391; regulation of membrane potential	5.239E-05	3.920E-03	ADRA1A, ADRB2, CHRNA3, CNR2, KCNH2, TRPV1
BP	GO:0007610; behavior	GO:0035095; behavioral response to nicotine	5.912E-05	4.278E-03	CHRNA3, PPARA
MF	GO:0005488; binding	GO:0019825; oxygen binding	6.139E-05	4.383E-03	CYP2C19, CYP2C9, CYP3A4
BP	GO:0009987; cellular process	GO:0010700; negative regulation of norepinephrine secretion	7.874E-05	5.365E-03	ADRA2A, ADRA2C
BP	GO:0023052; signaling	GO:0051584; regulation of dopamine uptake involved in synaptic transmission	7.874E-05	5.365E-03	DRD2, DRD3
MF	GO:0060089; molecular transducer activity	GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go	7.874E-05	5.365E-03	DRD2, DRD3
BP	GO:0032501; multicellular organismal process	GO:0032922; circadian regulation of gene expression	1.122E-04	7.259E-03	DRD2, DRD3, PPARA
BP	GO:0009987; cellular process	GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway	1.263E-04	8.064E-03	DRD2, DRD3
BP	GO:0008152; metabolic process	GO:0097267; omega-hydroxylase P450 pathway	1.263E-04	8.064E-03	CYP2C19, CYP2C9
BP	GO:0050896; response to stimulus	GO:0034776; response to histamine	1.542E-04	9.565E-03	DRD2, DRD3
MF	GO:0005488; binding	GO:0005506; iron ion binding	1.538E-04	9.565E-03	ALOX15, CYP2C19, CYP2C9, CYP3A4
BP	GO:0009987; cellular process	GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway	3.594E-18	1.118E-14	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, DRD2
MF	Unclassified;	GO:0004872; receptor activity	1.279E-15	1.741E-12	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, CHRNA3, CNR2, DRD2, DRD3, FFAR1, FFAR4, HTR1A, HTR2A, HTR2B, HTR2C, HTR7, KCNH2, PPARA, TRPV1
CC	GO:0044425; membrane part	GO:0005887; integral component of plasma membrane	6.767E-14	4.912E-11	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, CNR2, DRD2, DRD3, FFAR1, FFAR4, HTR1A, HTR2A, HTR2B, HTR2C, HTR7, SLC6A4, TRPV1

Enriched KEGG Pathways of Target Proteins (Activity≤1μM)

Top 10 KEGG Pathways (ordered by adjusted p-value)

Detailed Information of Enriched KEGG Pathways

Pathway Category Top Level	Pathway Category Second Level	Pathway ID	Pathway Name	p-Value	Adjusted p-Value	Enriched Genes
09130 Environmental Information Processing	09133 Signaling molecules and interaction	hsa04080	Neuroactive ligand-receptor interaction	1.483E-23	7.414E-22	CHRNA3, HTR1A, HTR2B, HTR2C, ADRB1, ADRA1D, ADRB2, TRPV1, HTR2A, ADRA2C, ADRA1B, ADRA1A, ADRA2A, HTR7, CNR2, DRD2, DRD3
09150 Organismal Systems	09156 Nervous system	hsa04726	Serotonergic synapse	1.672E-15	4.180E-14	CYP2C9, HTR7, MAOB, ALOX15, HTR1A, HTR2B, HTR2C, HTR2A, CYP2C19, SLC6A4
09130 Environmental Information Processing	09132 Signal transduction	hsa04020	Calcium signaling pathway	1.015E-11	1.691E-10	HTR7, HTR2B, HTR2C, ADRB1, ADRA1D, ADRB2, HTR2A, ADRA1B, ADRA1A
09130 Environmental Information Processing	09132 Signal transduction	hsa04022	cGMP-PKG signaling pathway	8.877E-09	1.110E-07	ADRB1, ADRA1D, ADRB2, ADRA2C, ADRA1B, ADRA1A, ADRA2A
09150 Organismal Systems	09154 Digestive system	hsa04970	Salivary secretion	3.351E-07	2.393E-06	ADRB1, ADRA1D, ADRB2, ADRA1B, ADRA1A
09140 Cellular Processes	09144 Cellular community - eukaryotes	hsa04540	Gap junction	3.166E-07	2.393E-06	HTR2B, HTR2C, ADRB1, HTR2A, DRD2
09100 Metabolism	09103 Lipid metabolism	hsa00591	Linoleic acid metabolism	1.417E-07	1.417E-06	CYP2C9, ALOX15, CYP3A4, CYP2C19
09150 Organismal Systems	09153 Circulatory system	hsa04261	Adrenergic signaling in cardiomyocytes	4.164E-06	2.461E-05	ADRB1, ADRA1D, ADRB2, ADRA1B, ADRA1A
09100 Metabolism	09111 Xenobiotics biodegradation and metabolism	hsa00982	Drug metabolism - cytochrome P450	4.922E-06	2.461E-05	CYP2C9, MAOB, CYP3A4, CYP2C19
09130 Environmental Information Processing	09132 Signal transduction	hsa04024	cAMP signaling pathway	1.755E-05	7.977E-05	HTR1A, ADRB1, ADRB2, PPARA, DRD2
09150 Organismal Systems	09157 Sensory system	hsa04750	Inflammatory mediator regulation of TRP channels	1.989E-05	8.286E-05	HTR2B, HTR2C, TRPV1, HTR2A
09150 Organismal Systems	09152 Endocrine system	hsa03320	PPAR signaling pathway	4.922E-06	2.461E-05	FABP3, FABP4, FABP5, PPARA
09150 Organismal Systems	09152 Endocrine system	hsa04923	Regulation of lipolysis in adipocytes	1.069E-04	4.111E-04	FABP4, ADRB1, ADRB2
09100 Metabolism	09103 Lipid metabolism	hsa00590	Arachidonic acid metabolism	1.448E-04	5.173E-04	CYP2C9, ALOX15, CYP2C19
09100 Metabolism	09108 Metabolism of cofactors and vitamins	hsa00830	Retinol metabolism	1.667E-04	5.558E-04	CYP2C9, ALDH1A1, CYP3A4
09160 Human Diseases	09161 Cancers	hsa05204	Chemical carcinogenesis	3.316E-04	1.036E-03	CYP2C9, CYP3A4, CYP2C19
09150 Organismal Systems	09153 Circulatory system	hsa04270	Vascular smooth muscle contraction	1.008E-03	2.964E-03	ADRA1D, ADRA1B, ADRA1A
09150 Organismal Systems	09156 Nervous system	hsa04728	Dopaminergic synapse	1.242E-03	3.449E-03	MAOB, DRD2, DRD3
09160 Human Diseases	09164 Substance dependence	hsa05030	Cocaine addiction	2.958E-03	7.784E-03	MAOB, DRD2

Human Diseases Associated with the Target Proteins of the Plant

Detailed Information of Human Diseases

ICD10 Disease Category	Disease Name	ICD10 Code	Associated Disease Targets (Association Ref: TTD database)
I00-I99: Diseases of the circulatory system	Congestive heart failure	I50	ADRA1D; HTR2B;
NA: NA	Cervical dystonia	NA	HTR1A;
K00-K95: Diseases of the digestive system	Gastric motility disorder	K22.4	DRD3;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Fibromyalgia	M79.7	ADRA2C; HTR2A; SLC6A4;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Huntington's disease	F02.2, G10	DRD2;
NA: NA	Hyperaemia	NA	DRD2;
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	Idiopathic thrombocytopenic purpura	D69.3	DRD2;
C00-D49: Neoplasms	Breast cancer	C50	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Insomnia	F51.0, G47.0	DRD2;
C00-D49: Neoplasms	Inflammatory disease	C11, C44, K75.9, M00-M25	CNR2; DRD2; SLC6A4;
K00-K95: Diseases of the digestive system	Inflammatory bowel disease	K50, K51	CNR2; DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Non-insulin dependent diabetes	E11.9	FFAR1;
C00-D49: Neoplasms	Non-small cell lung cancer	C33-C34	DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Obesity	E66	SLC6A4;
I00-I99: Diseases of the circulatory system	High blood pressure	I10-I16	ADRB1;
NA: NA	Itching	NA	DRD2;
G00-G99: Diseases of the nervous system G00-G99	Neurodegenerative disease	G30-G32	MAOB;
G00-G99: Diseases of the nervous system G00-G99	Neuropathic pain	G64, G90.0	CNR2; SLC6A4; TRPV1;
NA: NA	Neurogenic shock	NA	ADRB1;
N00-N99: Diseases of the genitourinary system	Neurogenic bladder dysfunction	N31.9	ADRB2;
I00-I99: Diseases of the circulatory system	Hemorrhoids	I84	HTR2A;
E00-E89: Endocrine, nutritional and metabolic diseases	Metabolic disorders	E70-E89	HTR2C;
E00-E89: Endocrine, nutritional and metabolic diseases	Eating disorder	E66, F50, I10-I16, I50	HTR1A;
I00-I99: Diseases of the circulatory system	Heart failure	I50	ADRA2C; ADRB1;
NA: NA	Heart block	NA	ADRB2;
I00-I99: Diseases of the circulatory system	Heart arrhythmia	I47-I49	ADRB1;
G00-G99: Diseases of the nervous system G00-G99	Migraine headaches	G43	DRD2; HTR2C;
G00-G99: Diseases of the nervous system G00-G99	Migraine	G43	ADRB1; HTR2A; HTR2B; SLC6A4; HTR1A;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Emesis	R11	DRD2; DRD3;
J00-J99: Diseases of the respiratory system	Nasal congestion	J34.89	DRD2;
I00-I99: Diseases of the circulatory system	Maintain blood pressure in hypotensive states	I10	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Major depression	F32, F33	SLC6A4;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Major depressive episode without melancholia	F30-F39	MAOB;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Male sexual disorders	F52	ADRA2C; DRD3;
NA: NA	Esophagus sensitivity	NA	TRPV1;
NA: NA	Episode	NA	HTR1A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Erectile dysfunction	F52.2, N48.4	ADRA1D;
L00-L99: Diseases of the skin and subcutaneous tissue	Erythema	L51-L54	ADRA2C;
H00-H59: Diseases of the eye and adnexa	Glaucoma	H40-H42	ADRA1A; ADRA1D; ADRA2C; ADRB1; DRD2; HTR2A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Generalized anxiety disorder	F32, F40-F42, F41.1	HTR2C; HTR1A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychoses	F20-F29	HTR2B;
NA: NA	Malignant phaeochromocytoma	NA	DRD2;
NA: NA	Menopausal staging	NA	SLC6A4;
K00-K95: Diseases of the digestive system	Peptic ulcer	K25-K27	ADRA2C;
E00-E89: Endocrine, nutritional and metabolic diseases	Carcinoid syndrome	E34.0	DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Exogenous obesity	E66	ADRA1B;
NA: NA	Exacerbations of acute asthma	NA	ADRB2;
K00-K95: Diseases of the digestive system	Gastroesophageal reflux disease	K21	TRPV1;
K00-K95: Diseases of the digestive system	Gastrointestinal problems	K30-K31, Q40-Q41	DRD2;
NA: NA	Appetite suppressant	NA	SLC6A4;
I00-I99: Diseases of the circulatory system	Ventricular fibrillation	I49.01	ADRB1;
NA: NA	Ventricular premature beats	NA	ADRB1;
NA: NA	Bradycardia	NA	ADRB2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Cough	R05	CHRNA3; TRPV1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Depression	F30-F39	ADRA2C; HTR2A; HTR2B; HTR2C; SLC6A4; MAOB; HTR1A;
NA: NA	Inflammatory diseases	NA	DRD2;
A00-B99: Certain infectious and parasitic diseases	Bacterial infections	A00-B99	CYP2C9; DRD2; MAOB;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Attention deficit hyperactivity disorder	F90	ADRA1B; ADRA2A; SLC6A4;
L00-L99: Diseases of the skin and subcutaneous tissue	Atopic dermatitis	L00-L99	CNR2; TRPV1;
N00-N99: Diseases of the genitourinary system	Vasomotor symptoms	N95.1	SLC6A4;
N00-N99: Diseases of the genitourinary system	Benign prostatic hyperplasia	N40	ADRA1A; ADRA1D;
NA: NA	Benign prostatic hypertrophy	NA	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Bipolar disorder	F31, F40-F42	DRD2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Depressive fatigue	R53.82	DRD2;
NA: NA	Depressive disorders	NA	SLC6A4;
K00-K95: Diseases of the digestive system	Dermal necrosis	K05	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Dementia	F01-F07	MAOB;
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetes	E23.2, N25.1	ADRA1D; ADRB1; HTR2A; HTR2C; FFAR1;
A00-B99: Certain infectious and parasitic diseases	Sepsis	A40, A41	ADRB1;
L00-L99: Diseases of the skin and subcutaneous tissue	Fibrosis	L90.5	DRD2;
N00-N99: Diseases of the genitourinary system	Urinary incontinence	N39.3, N39.4, R32	ADRA1A; ADRA1D; TRPV1; HTR1A;
G00-G99: Diseases of the nervous system G00-G99	Acute migraine	G43	TRPV1;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Acute or chronic pain	R52, G89	TRPV1;
E00-E89: Endocrine, nutritional and metabolic diseases	Acromegaly	E22.0	DRD2;
J00-J99: Diseases of the respiratory system	Acute asthma	J45	ADRB2;
I00-I99: Diseases of the circulatory system	Cardiotonic	I50	DRD2;
I00-I99: Diseases of the circulatory system	Cardiovascular disorder	I00-I99	HTR2A;
I00-I99: Diseases of the circulatory system	Cardiac arrhythmias	I47-I49	ADRB1;
I00-I99: Diseases of the circulatory system	Cardiac failure	I50	DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic nephropathy	E11.21	ADRA2C;
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic neuropathy	E11.40	TRPV1;
I00-I99: Diseases of the circulatory system	Maintenance of normal sinus rhythm	I46-I49	ADRB1;
C00-D49: Neoplasms	Cancer	C00-C96	SLC6A4;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Cachexia	R64	ADRB2;
NA: NA	Bulimia nervosa	NA	HTR1A;
J00-J99: Diseases of the respiratory system	Bronchodilator	J45	ADRB1; ADRB2;
J00-J99: Diseases of the respiratory system	Bronchitis	J20-J21, J42	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Drug abuse	F10-F19	DRD3; HTR2C; CHRNA3;
N00-N99: Diseases of the genitourinary system	Prostate disease	N42.9	ADRA1A; ADRA1D;
O00-O9A: Pregnancy, childbirth and the puerperium	Premature labour	O60.1, P07.3	ADRB2;
NA: NA	Primary insomnia	NA	HTR2C;
L00-L99: Diseases of the skin and subcutaneous tissue	Aging skin	L00-L99	ADRB2;
C00-D49: Neoplasms	Aggressive non-hodgkin's lymphoma	C81, C81-C86, C82-C85, C91-C95	HTR2C;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Advanced stage Parkinson's disease	F02.3, G20	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Alcohol use disorders	F10.2	ADRA2C; DRD2; HTR2A; HTR2C;
A00-B99: Certain infectious and parasitic diseases	Irritable bowel syndrome	A09, K58, K59.1	HTR2B;
NA: NA	Chemotherapyinduced emesis	NA	SLC6A4;
J00-J99: Diseases of the respiratory system	Chronic breathing disorders	J44-J47	ADRB2;
E00-E89: Endocrine, nutritional and metabolic diseases	Erythropoietic porphyria	E80.0	HTR2A;
N00-N99: Diseases of the genitourinary system	Prostate hyperplasia	N40	ADRA1A; ADRA1D;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychosis	F20-F29	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychotic disorders	F20-F29	DRD2; DRD3; HTR2C; HTR1A;
I00-I99: Diseases of the circulatory system	Pulmonary arterial hypertension	I27.0, I27.2	HTR2B;
J00-J99: Diseases of the respiratory system	Allergic rhinitis	J00, J30, J31.0, T78.4	ADRA2C;
S00-T88: Injury, poisoning and certain other consequences of external causes	Allergy	T78.4	ADRB1; DRD2;
G00-G99: Diseases of the nervous system G00-G99	Alzheimer disease	G30	ADRA2C; DRD2; MAOB; HTR1A;
J00-J99: Diseases of the respiratory system	Chronic obstructive pulmonary disease	J40-J44, J47	ADRB2; DRD2;
I00-I99: Diseases of the circulatory system	Cerebral infarction	I63	HTR2B;
G00-G99: Diseases of the nervous system G00-G99	Central nervous system disease	G00-G99	HTR2A; MAOB;
G00-G99: Diseases of the nervous system G00-G99	Central and peripheral nervous diseases	G96.9	ADRB1;
I00-I99: Diseases of the circulatory system	Cerebrovascular ischaemia	I61-I63	DRD2;
C00-D49: Neoplasms	Overactive bladder disorder	C67, N32.81	TRPV1;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Osteoporosis	M80-M81, Z79.890	CNR2;
C00-D49: Neoplasms	Prostate cancer	C61	ADRA1A;
NA: NA	Cardiogenic shock	NA	ADRB1;
NA: NA	Angina	NA	ADRB1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Post-traumatic stress disorder	F43.1	ADRA1A;
I00-I99: Diseases of the circulatory system	Circulatory disorders	I00-I99	ADRB1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cocaine addiction	F14.2	DRD3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cognitive disorders	F01-F07, F04, F05, R41.3	ADRA1A; MAOB; HTR1A;
A00-B99: Certain infectious and parasitic diseases	Postherpetic neuralgia	B02.2, G44.847, G53.0	TRPV1;
O00-O9A: Pregnancy, childbirth and the puerperium	Postpartum haemorrhage	O72	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Premature ejaculation	F52.4	ADRB2; SLC6A4; HTR1A;
NA: NA	Anxiety disorders	NA	HTR1A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Anxiety disorder	F32, F40-F42	CYP3A4; DRD2; HTR2A; HTR2C; MAOB; HTR1A;
NA: NA	Peripheral vasoconstriction	NA	DRD2;
S00-T88: Injury, poisoning and certain other consequences of external causes	Poison intoxication	T36-T50	ADRA2C;
I00-I99: Diseases of the circulatory system	Peripheral vascular disease	I73.9	ADRA1D;
NA: NA	Peripheral sensory neuropathies	NA	HTR1A;
NA: NA	Chronic low back pain	NA	SLC6A4;
H00-H59: Diseases of the eye and adnexa	Chronic open-angle glaucoma	H40	ADRB1;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Chronic pathological pain	R52, G89	TRPV1;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Chronic pain	R52.1-R52.2, G89	SLC6A4;
L00-L99: Diseases of the skin and subcutaneous tissue	Skin infections	L00-L99	ADRB2;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Rheumatoid arthritis	M05-M06	CNR2;
NA: NA	Schizoaffective disorder	NA	HTR1A;
NA: NA	Schizoaffective disorders	NA	DRD2;
I00-I99: Diseases of the circulatory system	Neurological disease	I21, I22, R52, R52.1-R52.2, R60.9, G89	ADRA2C; HTR2C;
I00-I99: Diseases of the circulatory system	Moderate to severe hypertension	I10-I16	MAOB;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Mood disorder	F30-F39	HTR2A; HTR2C; SLC6A4; HTR1A;
I00-I99: Diseases of the circulatory system	Pulmonary hypertension	I27.0, I27.2	DRD2;
NA: NA	Malignant essential hypertension	NA	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Major depressive disorder	F32, F33, M32	HTR7; ADRA1A; DRD2; HTR2C; SLC6A4; MAOB; HTR1A;
A00-B99: Certain infectious and parasitic diseases	Septic shock	A41.9	ADRB1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Schizophrenia	F20	HTR7; DRD2; DRD3; HTR2A; HTR2C; SLC6A4; HTR1A;
NA: NA	Motor symptoms	NA	MAOB;
NA: NA	Myalgia	NA	SLC6A4;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Musculoskeletal pain	R52, G89	TRPV1;
E00-E89: Endocrine, nutritional and metabolic diseases	Type 2 diabetes	E11	FFAR1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sleep maintenance insomnia	F51.0, G47.0	HTR2A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Severe mood disorders	F30-F39	HTR1A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sexual dysfunction	F52	ADRA2A; DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sleep disorders	F51, G47	HTR7; HTR2A;
NA: NA	Sleep initiation and maintenance disorders	NA	HTR2C;
NA: NA	Social phobia	NA	HTR1A;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Spasm	R25.2	HTR1A;
H00-H59: Diseases of the eye and adnexa	Ocular hypertension	H40.0	ADRA2C; ADRB1; ADRB2;
H00-H59: Diseases of the eye and adnexa	Ocular disease	H00-H59	ADRA2C;
H00-H59: Diseases of the eye and adnexa	Open-angle glaucoma	H40-H42	ADRB1;
H00-H59: Diseases of the eye and adnexa	Ophthalmic disease	H00-H59	DRD2;
I00-I99: Diseases of the circulatory system	Angina pectoris	I20	ADRB1; DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Substance dependence	F10-F19	DRD2;
N00-N99: Diseases of the genitourinary system	Stress urinary incontinence	N39.3	ADRA1A;
C00-D49: Neoplasms	Pediatric cancer	C00-C96	ADRA1D;
G00-G99: Diseases of the nervous system G00-G99	Pain	G64, G90.0, R52, G89	CNR2; ADRA1A; ADRA2A; ADRA2C; DRD2; HTR2C; SLC6A4; TRPV1; HTR1A;
K00-K95: Diseases of the digestive system	Pancreatitis	K85, K86.0K86.1	HTR2A;
G00-G99: Diseases of the nervous system G00-G99	Parkinson's disease	G20	DRD2; SLC6A4; MAOB; HTR1A;
NA: NA	Addiction	NA	HTR2A;
I00-I99: Diseases of the circulatory system	Acute supraventricular tachycardia	I47.1	ADRB1;
J00-J99: Diseases of the respiratory system	Asthma	J45	ADRA2C; ADRB2; DRD2; TRPV1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Idiopathic parkinson's disease	F02.3, G20	MAOB;
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	Immune disorder	D80-D89	CNR2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychiatric disorder	F01-F99	ADRA1B; HTR2A; HTR1A;
I00-I99: Diseases of the circulatory system	Hypotension	I95	ADRA2C; DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Hypoactive sexual desire disorder	F52.0	HTR1A;
NA: NA	Vomiting	NA	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Smoking cessation	F17.2	SLC6A4;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Female sexual dysfunction	F52	ADRA1A; DRD3; HTR1A;
G00-G99: Diseases of the nervous system G00-G99	Lateral sclerosis	G12.2	HTR1A;
I00-I99: Diseases of the circulatory system	Coronary heart disease	I25.1	HTR2B;
NA: NA	Corneal vascularity	NA	DRD2;
I00-I99: Diseases of the circulatory system	Coronary artery disease	I20-I25	ADRB1; HTR1A;
S00-T88: Injury, poisoning and certain other consequences of external causes	Contusion	S36.220S	ADRA2C;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Nausea	R11	DRD2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Fecal incontinence	R15	ADRA1D;
NA: NA	False perceptions	NA	DRD2;
I00-I99: Diseases of the circulatory system	Hypertension	I10-I16	ADRA1A; ADRA1B; ADRA1D; ADRA2C; ADRB1; ADRB2; DRD2; HTR1A;
E00-E89: Endocrine, nutritional and metabolic diseases	Hyperprolactinemia	E22.1	DRD2;

Data Section	Select to Download
1. General Info & Plant Usage & Geographical Distribution
2. Human Target Proteins
3. Target Gene Ontology
4. Target KEGG Pathway
5. Related Human Diseases